Moreover, a significant beneficial impact of DR was also detected in the subgroup of patients with ≤2 risk factors for CKI-AKI (n = 27) with a decrease in creatinine of −0.06 (−0.12,0.07) mg/dL at 24 h and of −0.01 (−0.18,0.07) mg/dL at 48 h in the DR group vs. an increase of 0.02 (−0.03,0.14) mg/dL at 24 h and 0.09(−0.03,0.16) mg/dL at 48 h in the control group (24 h: p = 0.039; 48 h: p = 0.030), respectively. The gene discussed is CHKA; the disease is acute kidney injury.